Latest Targeted therapy Stories
RnRMarketResearch.com adds “Erbitux (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ -- [[CENTER] ]http://www.abmrg.com/Global-Oncology-Market---Trends-Forecast-and-Pipeline-Analysis.html
NORWALK, Conn., Nov.
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Data from 13 accepted abstracts include: NORTH CHICAGO, Ill., Nov.
SAN DIEGO and BARCELONA, Spain, Nov.
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
- To fire mitraille at.